GURU.Markets stock price, segment price, and overall market index valuation
The company's share price INMB
INmune Bio is a biotech company developing immunotherapies for cancer and Alzheimer's disease. Its stock price is volatile and dependent on clinical trial results. The chart reflects investor hopes for breakthroughs in these complex areas.
Share prices of companies in the market segment - Pharma immune
INmune Bio is a biopharmaceutical company developing drugs targeting innate immunity to treat cancer, Alzheimer's, and other diseases. We've categorized it as "Pharma: Immunology." The chart below shows how investors value companies with a broad pipeline.
Broad Market Index - GURU.Markets
INmune Bio is a biopharmaceutical company developing drugs targeting innate immunity to treat cancer, Alzheimer's, and other diseases. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
INMB - Daily change in the company's share price INMB
INmune Bio, Inc.'s daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its Alzheimer's and cancer treatments.
Daily change in the price of a set of shares in a market segment - Pharma immune
INmune Bio, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with the immunology-focused INMB helps assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
INmune Bio is a biotech company working in the field of immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization INMB
For INmune Bio, Inc., year-over-year performance is a story about its multidisciplinary approach to treating inflammatory diseases. Its 12-month market cap depends on progress in its programs targeting Alzheimer's disease, cancer, and other conditions associated with chronic inflammation. Success in any of these areas could be a breakthrough.
Annual dynamics of market capitalization of the market segment - Pharma immune
INmune Bio, Inc. is a clinical-stage biotech company developing immunotherapies for the treatment of cancer and Alzheimer's disease. Its stock price is entirely dependent on clinical trial results. The chart reflects the high risks and enormous potential of its scientific platform.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
INmune Bio is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization INMB
INmune Bio is a clinical-stage biotech focused on immunology and Alzheimer's disease. Its monthly performance is entirely dependent on the results of its clinical trials. Data from its key programs is a binary outcome for its stock.
Monthly dynamics of market capitalization of the market segment - Pharma immune
INmune Bio is a biotech company focused on reprogramming the innate immune system to combat cancer, Alzheimer's, and other inflammatory diseases. The chart below reflects the overall sentiment in the immunopharma sector, where INmune Bio is at the forefront of science.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
INmune Bio, Inc. is a biotech company targeting the immune system to treat cancer and Alzheimer's disease. Its shares move in sync with clinical trial news. The company's performance is uncorrelated with the market and represents a high-risk bet on the success of its innovative approach.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization INMB
Short-term volatility in INmune Bio, a biopharmaceutical company targeting the immune system to treat cancer and Alzheimer's disease, is extremely high. News about the progress of its various clinical programs causes sharp and often unpredictable stock movements.
Weekly dynamics of market capitalization of the market segment - Pharma immune
INmune Bio and the entire immunology biotech sector are driven by overall investor sentiment and news of breakthroughs. The success or failure of one major study can impact the entire industry. This chart shows how the company fares against this volatile backdrop.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
INmune Bio and the entire immunology biotech sector are driven by overall investor sentiment and news of breakthroughs. The success or failure of one major study can impact the entire industry. This chart shows how the company fares against this volatile backdrop.
Market capitalization of the company, segment and market as a whole
INMB - Market capitalization of the company INMB
INmune Bio's market capitalization is the financial valuation of a biotech company targeting the immune system to treat cancer, Alzheimer's, and other diseases. The chart reflects investor expectations for its broad, yet risky, pipeline of developments. Its volatile dynamics tell the story of how the market reacts to each step in clinical trials.
INMB - Share of the company's market capitalization INMB within the market segment - Pharma immune
INmune Bio is a clinical-stage biotech company focused on treating diseases related to innate immunity, including cancer and Alzheimer's disease. Its sector share reflects its innovative approach to the immune system. The chart below is an indicator of the market's faith in its science.
Market capitalization of the market segment - Pharma immune
INmune Bio is a biopharmaceutical company targeting the immune system to treat cancer and neurodegenerative diseases. The chart below shows the overall market capitalization of the sector. Its dynamics reflect the hope that managing inflammation will be key to treating many diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
The immunology shown in the graph fights inflammation. INmune Bio develops drugs that target chronic inflammation, which is believed to play a role in Alzheimer's disease and cancer. Its capitalization is a risky bet on this broad and promising scientific hypothesis.
Book value capitalization of the company, segment and market as a whole
INMB - Book value capitalization of the company INMB
INmune Bio's schedule is capitalized on fighting inflammation, the underlying cause of many diseases. Currently in the R&D stage, the company is using its financial assets to develop drugs targeting neuroinflammation in Alzheimer's disease and immunotherapy resistance in cancer.
INMB - Share of the company's book capitalization INMB within the market segment - Pharma immune
INmune Bio, a biopharmaceutical company, focuses on the treatment of inflammation and cancer. Its share of the sector's assets consists of R&D laboratories. Its value lies in its scientific platform, which targets the regulation of innate immunity, rather than in its manufacturing capabilities.
Market segment balance sheet capitalization - Pharma immune
INmune Bio, Inc. is a clinical-stage immuno-oncology company, making its model asset-light. The company's value lies in its scientific platform and clinical trial data. Compared to the biotech sector as a whole, its low capital intensity is typical of innovative R&D companies.
Book value of all companies included in the broad market index - GURU.Markets
INmune Bio's assets represent more than just a single drug, but an entire platform aimed at reprogramming the innate immune system to combat cancer, Alzheimer's, and other diseases. The company's balance sheet reflects the value of this comprehensive approach. The chart shows how much capital is invested in managing the immune system's "conductor."
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - INMB
INmune Bio is a biotech company targeting the immune system to treat cancer and Alzheimer's disease. Its market value is based on its broad and ambitious research portfolio. Investors are betting on its potential to make breakthroughs in multiple areas.
Market to book capitalization ratio in a market segment - Pharma immune
INmune Bio is a biotech company targeting the immune system to treat cancer, Alzheimer's, and other diseases. Its value reflects the potential of its broad scientific platform. This chart shows how the market values this promising, yet risky, pipeline.
Market to book capitalization ratio for the market as a whole
INmune Bio is a biotech company developing immune-targeted drugs for the treatment of cancer and Alzheimer's disease. Its market capitalization is based on the potential of its scientific platform. The chart shows the enormous premium investors pay for research in the most complex areas of medicine, compared to the market average.
Debts of the company, segment and market as a whole
INMB - Company debts INMB
INmune Bio is a biotech company targeting the immune system to treat cancer and neurodegenerative diseases. Funding such a broad and ambitious research agenda requires significant resources. This chart shows how the company is raising capital to support its various clinical programs.
Market segment debts - Pharma immune
INmune Bio is a clinical-stage biotech company specializing in treating diseases related to inflammation and the immune system. This chart shows whether the company is pursuing the industry-standard equity financing model to advance its innovative approaches to treating Alzheimer's disease and cancer.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio INMB
INmune Bio, a biopharmaceutical company targeting the immune system to treat cancer and Alzheimer's disease, shows its reliance on debt. Drug development in these areas is incredibly complex and expensive. High debt means the company has virtually no margin for failure in clinical trials.
Market segment debt to market segment book capitalization - Pharma immune
INmune Bio is a biopharmaceutical company targeting the immune system to combat cancer and neurodegenerative diseases like Alzheimer's. This chart compares the debt it raised for this ambitious research with the overall market capitalization of the entire immune pharmaceutical sector, demonstrating the financial implications of this innovative approach.
Debt to book value of all companies in the market
INmune Bio is a biotech company focused on immunotherapy for cancer and neurodegenerative diseases. Funding clinical trials is its primary focus. The chart shows how the company manages its debt. Its financial structure, compared to the biotech market, reflects the stage of development and investor confidence in its scientific approach.
P/E of the company, segment and market as a whole
P/E - INMB
This chart for INmune Bio, a biopharmaceutical company targeting the immune system to treat cancer and Alzheimer's, is an assessment of its bold scientific approach. The stock price relative to potential earnings reflects investors' belief that managing inflammation is the key to treating these diseases. The stock's performance reflects the company's reaction to the research data.
P/E of the market segment - Pharma immune
This chart reflects the average valuation for the speculative biotech sector—a benchmark for INmune Bio. For investors, it's a benchmark indicating the overall level of optimism. Against this backdrop, one can gauge expectations for the company's bold approach to treating cancer and Alzheimer's disease through inflammation management.
P/E of the market as a whole
INmune Bio is a biotech company focused on treating inflammation-related diseases, including Alzheimer's and cancer. Its approach is to target the immune system to combat these pathologies. This chart shows the market's risk appetite. It allows us to understand how investors view this promising but risky approach and how data from various clinical programs influences the company's valuation.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company INMB
INmune Bio is a biotech company focused on harnessing the immune system to treat cancer, Alzheimer's, and other diseases. This chart reflects analysts' aggregate expectations for its diverse pipeline. It demonstrates market confidence that its approach to modulating innate immunity could lead to breakthroughs.
%20P%2FE%20INMB&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-INMB&v=1772569287603 "Chart of the company's future (projected) P/E INMB")
Future (projected) P/E of the market segment - Pharma immune
INmune Bio is a biopharmaceutical company focused on treating diseases related to innate immunity, including cancer, Alzheimer's disease, and NASH. This chart compares its future profitability expectations with the biotech sector. It demonstrates how the market views its broad scientific platform and its ambitions to treat multiple complex diseases.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772569287633 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
INmune Bio is a clinical-stage biopharmaceutical company targeting the immune system to combat cancer and Alzheimer's disease. This chart shows the company's overall risk appetite. INMB's success depends on clinical trial results. A positive market environment helps with funding but is no substitute for scientific data.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772569287667 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit INMB
INmune Bio is a clinical-stage immuno-oncology company focused on reprogramming the innate immune system to fight cancer and other diseases. This chart shows the financial trajectory of this new immunotherapy approach. Results reflect investments in clinical research.
Profit of companies in the market segment - Pharma immune
INmune Bio is a biopharmaceutical company developing drugs that reprogram the innate immune system to fight cancer, Alzheimer's, and other diseases. This chart shows the financial pulse of the immunopharmaceutical sector, reflecting the potential of new approaches targeting key immune response mechanisms.
Overall market profit
INmune Bio is a biotech company targeting the immune system to treat cancer and Alzheimer's disease. Its success depends on the results of clinical trials. The company's business is not affected by economic cycles. However, as with other biotech companies, the availability of capital for research depends on the overall state of the financial markets.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company INMB
INmune Bio is a biotech company focused on reprogramming the innate immune system to combat cancer, Alzheimer's, and other diseases. This chart reflects analysts' long-term and speculative expectations regarding the success of its broad and ambitious scientific platform.
%20profit%20of%20the%20company%20INMB&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-INMB&v=1772569287807 "Graph of future (projected) profit of the company INMB")
Future (predicted) profit of companies in the market segment - Pharma immune
INmune Bio is a biopharmaceutical company focused on treating diseases related to innate immunity, including cancer and Alzheimer's disease. This chart shows forecasts for the biotech sector. INmune Bio's unique approach to reprogramming the immune system opens new opportunities, but its future profitability depends on success in clinical trials.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772569287813 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
INmune Bio is a biotech company targeting the immune system to treat cancer and neurodegenerative diseases. Its ability to fund research depends on market sentiment. This chart, which displays overall earnings expectations, is an indicator of investor risk appetite, which is critical for companies in clinical development.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772569287814 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - INMB
INmune Bio is a biopharmaceutical company focused on treating diseases related to innate immunity, including cancer and Alzheimer's disease. This chart reflects its valuation based on scientific potential, highlighting investor expectations that its approach to the immune system will lead to breakthrough treatments.
P/S market segment - Pharma immune
INmune Bio is a biopharmaceutical company focused on treating diseases related to innate immunity, including cancer, Alzheimer's, and liver disease. Its approach is aimed at reprogramming the immune system. This chart reflects the average biotech valuation, helping to understand how highly the market values this innovative and broad scientific platform.
P/S of the market as a whole
INmune Bio is a biotech company focused on harnessing the immune system to combat cancer and neurodegenerative diseases such as Alzheimer's. This revenue valuation indicator emphasizes that investors are evaluating not current sales, but the scientific potential of the company's platform in the most complex areas of medicine.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company INMB
INmune Bio is a biopharmaceutical company developing drugs targeting the innate immune system to treat cancer and neurodegenerative diseases such as Alzheimer's. This chart reflects investor confidence in this new approach. The valuation is based on the potential future revenue from its drugs if clinical trials are successful.
%20P%2FS%20INMB&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-INMB&v=1772569287917 "The graph of the company's future (projected) P/S INMB")
Future (projected) P/S of the market segment - Pharma immune
INmune Bio is a biopharmaceutical company focused on treating inflammation-related diseases, including Alzheimer's and cancer. This chart compares the company's future revenue expectations with its industry sector, reflecting investor confidence in its scientific approach to treating these complex diseases.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772569287938 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
INmune Bio is a clinical-stage immuno-oncology company focused on reprogramming the innate immune system to fight cancer. This schedule reflects confidence in future growth, and INmune Bio is working on a fundamentally new approach. The success of its therapy could open new horizons in the treatment of cancer and neurodegenerative diseases.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772569287949 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales INMB
INmune Bio is a clinical-stage biopharmaceutical company targeting the immune system for the treatment of cancer and Alzheimer's disease. The company currently has no commercial sales revenue. Any revenue reflected in this chart likely comes from grants or early partnerships.
Sales of companies in the market segment - Pharma immune
INmune Bio is a biotech company focused on treating diseases associated with chronic inflammation in the immune system, including Alzheimer's disease and cancer. This graph reflects a growing understanding of the immune system's role in various diseases, opening up new therapeutic opportunities for companies like INmune.
Overall market sales
INmune Bio, Inc. is an immunology company developing drugs to treat cancer and neurodegenerative diseases. Its future depends on the success of clinical trials. The growth in total economic revenue, reflected in this chart, improves the investment climate, making it easier for companies like INmune Bio to secure funding for expensive and time-consuming research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company INMB
INmune Bio, Inc. is a biopharmaceutical company developing drugs that target the innate immune system to combat cancer, Alzheimer's, and other diseases. This chart reflects analyst expectations for the success of clinical trials of its innovative immunotherapeutic approaches.
%20sales%20of%20the%20company%20INMB&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-INMB&v=1772569287997 "Schedule of future (projected) sales of the company INMB")
Future (projected) sales of companies in the market segment - Pharma immune
INmune Bio is a biopharmaceutical company developing drugs that target the innate immune system to combat cancer, Alzheimer's, and other diseases. This chart shows forecasts for the immune pharmacology sector, illustrating the growing interest in the immune system as a key to treating a wide range of diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772569288001 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
INmune Bio, an immunology company focused on cancer and Alzheimer's treatments, sees this chart as an indicator of investment appetite for breakthrough biotechnologies. The strong economics reflected here facilitate funding for long-term, high-risk, but potentially revolutionary research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772569288032 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality INMB
INmune Bio is a clinical-stage biotech company focused on reprogramming the innate immune system to combat cancer and Alzheimer's disease. This chart reflects the financial side of cutting-edge science, showing the company's investment in clinical trials of its innovative treatment approaches.
Market segment marginality - Pharma immune
INmune Bio is a biotech company targeting the immune system to combat cancer and neurodegenerative diseases like Alzheimer's. Efficiency here is the ability to advance innovative but risky programs while managing investor expectations and costs. The chart below shows their operating model.
Market marginality as a whole
INmune Bio is a clinical-stage biotech company focused on harnessing the innate immune system to treat cancer and Alzheimer's disease. This graph shows average profitability, and INmune Bio is working on a new treatment approach. Their success depends on proving their hypothesis in clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company INMB
INmune Bio is a clinical-stage immunology company focused on treating inflammatory diseases and cancer. Its team, visible in this graph, consists of scientists and clinicians. The size of its staff reflects the breadth of its research platform, which is aimed at reprogramming the innate immune system.
Share of the company's employees INMB within the market segment - Pharma immune
INmune Bio is a biopharmaceutical company targeting the immune system to treat cancer, Alzheimer's, and other diseases. This chart shows the percentage of all immunology researchers in the field that INmune attracts. This reflects its scientific potential and the breadth of its approach to treating diseases through immune modulation.
Number of employees in the market segment - Pharma immune
INmune Bio is a clinical-stage biopharmaceutical company targeting the immune system to combat cancer and Alzheimer's disease. Its staff consists of a small but experienced team of scientists and physicians. This graph illustrates its focused approach. Staff dynamics will reflect progress in clinical trials across multiple fronts.
Number of employees in the market as a whole
INmune Bio is a biopharmaceutical company focused on the immune system to combat cancer and Alzheimer's disease. Its headcount and market cap depend on scientific breakthroughs. This chart reflects overall headcount, but for INmune Bio, the publication of breakthrough data on Alzheimer's treatments will be far more significant.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company INMB (INMB)
INmune Bio is a biotech company working at the intersection of immunology and neuroscience. Its market capitalization is the market's valuation of its scientific hypotheses. The very high value on this chart is typical for an R&D company, where intellectual property is its primary asset.
%20of%20the%20company%20INMB%20(INMB)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-INMB-INMB&v=1772569288276 "Chart of market capitalization per employee (in thousands of dollars) of the company INMB (INMB)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
INmune Bio, Inc. is an immuno-oncology company focused on reprogramming the innate immune system to fight cancer. Its value is driven by its unique scientific platform. This chart shows the premium investors are paying for this innovative approach per scientist working on its implementation.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772569288288 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
INmune Bio is a biopharmaceutical company developing drugs that target the innate immune system to treat cancer, Alzheimer's, and other diseases. The chart shows a high valuation per employee, as investors see enormous potential in the company's innovative approach to treating a variety of serious diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772569288292 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company INMB (INMB)
INmune Bio is a biotech company focused on the immune system for the treatment of cancer, Alzheimer's, and other diseases. It's an R&D company. This chart shows the R&D capital burn per scientist. This represents an investment in scientific research that could generate significant profits in the future.
%20Chart%20INMB%20(INMB)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-INMB-INMB&v=1772569288303 "Company Profit Per Employee (in thousands of dollars) Chart INMB (INMB)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
INmune Bio (INMB) is a clinical-stage biopharmaceutical company specializing in immunotherapy targeting inflammatory diseases and oncology. This chart reflects R&D efficiency. It shows how efficiently the research team uses capital to advance its candidates (for example, for the treatment of Alzheimer's disease) through clinical trials.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772569288323 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
INmune Bio is a biotech company focused on the immune system for the treatment of cancer, Alzheimer's, and other diseases. The company is in the clinical stage. This chart shows the company's investment in research. Negative profit per employee is normal, as its research staff is focused on developing future treatments, not on current sales.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772569288338 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee INMB (INMB)
INmune Bio is a biopharmaceutical company targeting the immune system to treat cancer, Alzheimer's, and other diseases. During the research phase, this chart is an indicator of future potential. Any revenue per employee will likely come from strategic alliances rather than commercial sales.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-INMB-INMB&v=1772569288353 "Sales chart per company employee INMB (INMB)")
Sales per employee in the market segment - Pharma immune
INmune Bio is a biotech company specializing in immunotherapy targeting chronic inflammation in cancer, Alzheimer's, and other diseases. This chart shows the average revenue per employee in the sector. It serves as a benchmark, demonstrating the level of productivity required in this cutting-edge yet capital-intensive field.
Sales per employee for the market as a whole
INmune Bio, Inc. (INMB) is a biotech company focused on the immune system. They are developing drugs to treat Alzheimer's disease (targeting neuroinflammation) and cancer. They are an R&D company. This chart shows the current (minimum) partnership revenue per scientist.
Short shares by company, segment and market as a whole
Shares shorted by company INMB (INMB)
INmune Bio is a biopharmaceutical company developing immunotherapies targeting chronic inflammation in cancer, Alzheimer's disease, and MASH. This is a very broad scope. The chart reflects the skepticism of investors, who bet the company is spreading its resources too thin and will fail to bring any of its risky programs to fruition in these complex areas.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-INMB-INMB&v=1772569288410 "Short Shares Chart for the Company INMB (INMB)")
Shares shorted by market segment - Pharma immune
INmune Bio attacks diseases (from Alzheimer's to cancer) through a new target: neuroinflammation. This chart demonstrates the skepticism surrounding this entire niche. Its rise suggests that investors are massively betting against this new therapeutic strategy, expecting it to fail in clinical trials.
Shares shorted by the overall market
INmune Bio is attacking both cancer and Alzheimer's disease using the immune system. It's extremely ambitious and expensive. This chart measures overall fear. When investors are pessimistic, they distrust complex scientific narratives. They see INMB as a double-dip risk (both cancer and Alzheimer's) and prefer to exit before the market turmoil intensifies.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator INMB (INMB)
INmune Bio, Inc. is a biotech company targeting the immune system to treat cancer and Alzheimer's disease. The company's shares are extremely volatile in anticipation of data releases. This oscillator measures the strength of hype, showing when the stock is "overheated" (above 70) due to breakout expectations or "oversold" (below 30) due to a lack of news or setbacks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-INMB-INMB&v=1772569288507 "RSI 14 indicator chart for the company's stock INMB (INMB)")
RSI 14 Market Segment - Pharma immune
INmune Bio (INMB) is a "biotech" that "tames" the *innate* immune system. Their "thing" is an attack on *chronic inflammation*, which is believed to underlie *Alzheimer's* and *cancer*. The "Pharma immune" (biotech) sector thrives on news. RSI\_14\_Seg shows the "temperature" of the *entire* segment. It's vital to understand: is INMB's growth due to their R&D, or is *the entire* biotech sector "overheated"?
RSI 14 for the overall market
INmune Bio (INMB) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast INMB (INMB)
INmune Bio is a biotech company developing drugs targeting the innate immune system to treat cancer, Alzheimer's, and other inflammatory diseases. This chart shows the analysts' average 12-month forecast, representing their collective bet on the success of this broad but complex R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-INMB-INMB&v=1772569288526 "A chart showing analyst consensus forecasts for the expected stock price. INMB (INMB)")
The difference between the consensus estimate and the actual stock price INMB (INMB)
INmune Bio is a biotech company attempting to treat Alzheimer's disease and cancer by targeting "innate immunity" (neuroinflammation). This chart shows how far the current stock price differs from the "fair" value predicted by analysts. It reflects their belief in this groundbreaking yet complex scientific hypothesis.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-INMB-INMB&v=1772569288550 "A chart showing the difference between the consensus forecast and the actual stock price. INMB (INMB)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
INmune Bio is a biotech company attacking the root of many diseases—chronic inflammation. Its R&D targets Alzheimer's disease and cancer. This chart shows analysts' overall expectations for the entire immune pharma sector. It reflects whether experts believe that guiding the immune system is the key to treating the major diseases of the 21st century.
Analysts' consensus forecast for the overall market share price
INmune Bio is a biotech company specializing in tweaking the immune system to treat cancer and neurodegenerative diseases (Alzheimer's). This chart shows overall risk appetite. For INmune, which operates in two of the riskiest areas of medicine, overall market optimism is critical to funding lengthy and expensive clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index INMB
INmune Bio is a clinical-stage biotech company focused on treating inflammation, the root cause of many diseases. Their R&D pipeline aims to recalibrate the innate immune system to combat everything from Alzheimer's disease (neuroinflammation) to cancer. This chart is a pure R&D indicator, reflecting the market's fluctuating faith in their complex science and their progress in clinical trials.
AKIMA Market Segment Index - Pharma immune
INmune Bio (INMB) is a biopharmaceutical company targeting the immune system to treat diseases. Their programs cover oncology (NK cells) and neurodegenerative diseases (Alzheimer's), targeting inflammation. The chart shows the average index for the segment, helping investors assess how this multifaceted immune approach compares to the average risk in the pharma sector.
The AKIM Index for the overall market
INmune Bio is a biotech company focused on immunology (innate immunity) for the treatment of cancer and Alzheimer's disease (XPro). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific story, which is battling neuroinflammation, compares to overall economic trends.
